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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by non-reversible airflow limitation.
A common symptom of COPD is dyspnea or shortness of breath. Dyspnea may vary daily, with a large impact on
patients’ lives. Previous clinical trials used patient-reported outcome (PRO) measures that quantified dyspnea at
discrete intervals and hence did not reflect this variability. Recently the Shortness of Breath with Daily Activities
(SOBDA) questionnaire was developed as a PRO measure of dyspnea utilizing a daily diary. This confirmatory post
hoc meta-analysis of SOBDA data from a large clinical study program further supports the questionnaire and
clarifies the minimum threshold of SOBDA response.
Methods: Data from four clinical trials (DB2113361, NCT01313637; DB2113373, NCT01313650; DB2113360,
NCT01316900; DB2113374, NCT01316913) were analyzed. These 24-week trials were randomized, blinded studies
investigating the efficacy and safety of several COPD treatments. These post hoc analyses focused on the SOBDA
questionnaire properties. This electronic-diary consists of 13 items completed daily, in which patients rate their
breathlessness level during common daily activities. Resultant SOBDA scores were compared with related,
commonly used assessments: modified Medical Research Council Research Dyspnea Scale (mMRC), Baseline
Dyspnea Index (BDI), Transition Dyspnea Index (TDI), St George’s Respiratory Questionnaire (SGRQ), COPD
Assessment Test (CAT), and trough forced expiratory volume in 1 s (FEV1). The consistency, reliability, validity
(convergent, known groups), and responsiveness of the SOBDA questionnaire was assessed.
Results: In total, 4967 patients with COPD provided data for these analyses. The SOBDA questionnaire had high
internal consistency (Cronbach’s alpha = 0.936), high test-retest reliability (Pearson’s correlation coefficient = 0.86)
and convergent validity with related measures (SGRQ total score, Pearson’s correlation coefficient = 0.59; CAT,
Spearman rank-order correlation coefficient = 0.50). SOBDA scores were statistically significantly lower in responders
(as defined by TDI, SGRQ, CAT, and trough FEV1 levels) versus non-responders (p < 0.001 for all assessments and all
time points). Using an anchor-based method, the threshold of a minimum response was calculated as a SOBDA
score change of −0.2 (SOBDA score range = 1–4).
Conclusions: The reliability, validity, and responsiveness of the SOBDA questionnaire as a PRO measure to quantify
dyspnea was supported in a large clinical trial population of patients with moderate–very severe COPD.
Keywords: Chronic obstructive pulmonary disease, Dyspnea, Shortness of breath with daily activities questionnaire,
SOBDA, COPD, Patient-reported outcome, PRO, Shortness of breath
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation that is not fully
reversible [1, 2]. Patients with COPD report dyspnea
(also referred to as ‘shortness of breath’ or ‘breathless-
ness’ by the patient) when undertaking normal physical
activities [3], which impacts their health-related quality
of life (HRQoL) and often results in medical treatment
being sought [2, 4–6]. The relationship between dyspnea
and clinical lung function assessment is complex as dys-
pnea can only be measured from the patient’s perspec-
tive [7]. Physiological measures of lung function
commonly used in clinical trials, such as the forced ex-
piratory volume in 1 s (FEV1; calculated as a percentage
of that predicted for a person of the same age gender
and height, % predicted FEV1), are not always closely re-
lated to dyspnea and/or patients’ HRQoL [2, 5]. As dys-
pnea can vary on a day-to-day basis, the preferred
method to assess this symptom is via a daily patient-
reported diary [7].
Objectively understanding the efficacy of treatments
on dyspnea is critical to ensuring that patients receive
optimal care. Even though dyspnea may have a large im-
pact on the daily lives of patients [4], it has been difficult
to capture its daily variation within clinical trials [8].
There is currently no available patient-reported outcome
(PRO) measure for COPD-related dyspnea that can be
used in support of label-specific claims for US Food
and Drug Administration (FDA) approved therapies
[8]. The Shortness of Breath with Daily Activities
(SOBDA) questionnaire was developed to provide such
a measure [7–9].
The SOBDA questionnaire enables patients’ percep-
tions of the impact of dyspnea on their daily activities to
be measured and recorded daily in an electronic diary
(e-diary). It was developed following guidelines relating
to PRO measures from the FDA [9, 10]. Aligned with
these guidelines, the SOBDA questionnaire was first de-
veloped with data from a cohort of 40 patients with
COPD across all stages of disease severity, using focus
groups and cognitive debriefing sessions [9]. The usabil-
ity of the e-diary was assessed in this initial study [9],
with the final SODBA questionnaire only available as an
e-diary. A larger group of patients (N = 334) was in-
volved in a second study designed to test its hypothetical
framework and to reduce the number of items within
the original 37-item pool [7]. The final 13-item pool was
then validated using data from a cohort of patients with
moderate–severe COPD (N = 547) enrolled in a random-
ized clinical trial (RCT), to demonstrate the internal
consistency, reliability, and validity (convergent and
known-groups) of the questionnaire [8]. The next stage,
as recommended by the FDA [10], was to further valid-
ate the questionnaire within a large group of patients.
This confirmatory post hoc meta-analysis measured
the performance of the SOBDA questionnaire within a
large clinical trial patient population. The specific objec-
tives of these analyses were to a) further assess the reli-
ability and responsiveness of the SOBDA questionnaire
using data from four Phase III clinical trials investigating
umeclidinium (UMEC)/vilanterol (VI), and b) to refine
the SOBDA threshold of minimum response in a clinical
trial population.
Methods
Study design and patient inclusion criteria
This was a post hoc analysis of data (study number
201151) from four clinical trials (DB2113361, NCT01313
637; DB2113373, NCT01313650; DB2113360, NCT01316
900; DB2113374, NCT01316913) [11–13]. All four trials
were 24-week, randomized, blinded, parallel-group stud-
ies with similar designs (Additional file 1 and Additional
file 2) [11–13]. All patients were required to provide in-
formed consent. The four trials were approved by local
institutional review boards/ethics committees [11–13].
Patients were ≥40 years of age, current or former
smokers with a smoking history of ≥10 pack-years, and
had a physician diagnosis of COPD [1, 2]. Lung function
inclusion criteria were a post-albuterol FEV1/forced vital
capacity ratio <0.70 and a post-albuterol FEV1 of ≤70 %
of predicted normal. All patients had symptoms of dys-
pnea at baseline measured using the modified Medical
Research Council Dyspnea Scale (mMRC) [14] with a
score of at least 2 required. Patients with a current diag-
nosis of asthma or any clinical significant uncontrolled
disease were excluded [11–13]. These inclusion and ex-
clusion criteria were similar to those used in the three
SOBDA development studies [7–9], as the SOBDA ques-
tionnaire was developed specifically for use in clinical
trials of bronchodilators. Patients who met the eligibility
criteria at the screening visit completed a 7–10 day and 7–
14 day run-in period in DB2113361/DB2113373 [11, 13]
and DB2113360/DB2113374 [12] respectively, followed by
a 24-week treatment period.
These four trials tested several treatments. Patients were
randomized to receive one of the following: placebo,
tiotropium 18 mcg, UMEC 62.5 mcg, UMEC 125 mcg,
UMEC/VI 62.5/25 mcg, UMEC/VI 125/25 mcg, or VI
25 mcg (the specific treatments used in each trial are de-
tailed in Additional file 1) [11–13]. This post hoc analysis
focused on the performance of the SOBDA questionnaire
and did not investigate the efficacy of these treatments,
which have been previously published [11–13]. In these
trials, there were a total of ten study clinic visits in
DB2113361/DB2113373 [11, 13] and nine visits in
DB2113360/DB2113374 [12] (Additional file 2) conducted
on an outpatient basis, during which several assessments
were made. Patients were asked to complete the SOBDA
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questionnaire every day throughout the run-in and treat-
ment periods.
Assessments
To complete the SOBDA questionnaire patients
answered 13 items using an e-diary before going to bed
each night [7, 9]. Items followed the format of: ‘how
short of breath were you when…’ with a list of different
daily activities (e.g., ‘…you put on your shoes?’). Re-
sponse options included a range of four options from
‘not at all’ to ‘so severely that I did not do the activity’,
with an additional option of ‘I did not do the activity
today’. This last option was included as not all activities
were carried out by all patients every day. Therefore, re-
sponses were scored either as missing (‘I did not do the
activity’) or on a scale ranging from 1 (‘not at all’) to 4
(‘so severely that I did not do the activity’). These re-
sponses were used to create a daily mean SOBDA score
(mean of the non-missing items, provided at least 7 out
of 13 items were non-missing). Aggregated daily scores
were converted into weekly SOBDA summary scores
only if a daily score was recorded for at least 4 of the
7 days in that week [8]. A low SOBDA score indicated
low levels of dyspnea. As this was a multinational study
program, the SOBDA questionnaire was developed in
US English and translated into 38 languages using trans-
lation best practice guidelines [15, 16].
Clinician-rated mMRC was assessed as previously de-
scribed [12, 14, 17]. Interviewer administered Baseline
Dyspnea Index (BDI) and Transition Dyspnea Index
(TDI) were assessed using the methods detailed by
Mahler et al. [18]. The HRQoL assessment tools, St
George’s Respiratory Questionnaire (SGRQ) was com-
pleted in all four studies according to Jones et al. [19]
and the COPD Assessment Test (CAT) was completed
in DB2113360/DB2113374 according to Jones et al. [20].
Spirometry details for measuring trough FEV1 were pro-
vided in the primary publications relating to the four
studies [11–13].
Post hoc analyses
Two study populations were used in these analyses.
The run-in population comprised all patients who
completed the visit on Day 1, including those who
were not randomized, those who were randomized and
did not receive any study medication, and those who
were randomized and received study medication. The
intent-to-treat (ITT) population comprised all ran-
domized patients who received at least one dose of
study drug [11–13].
Consistency, reliability, and validity
The internal consistency of the SOBDA questionnaire
was assessed using Cronbach’s alpha (scale from 0 to 1.0,
with values ≥0.7 considered as indicative of internal
consistency) [21, 22], for all patients in the run-in popu-
lation who provided a score for each SOBDA item on
the first day of the run-in period. Test-retest reliability
was assessed in the ITT population for all patients who
provided enough data to calculate a SOBDA weekly
score at baseline and for the week before Day 28
(SOBDA score recorded on 4 of the 7 days prior to
those visits), and had a TDI score of 0 (a surrogate to
indicate no change in dyspnea) at the Day 28 visit.
Pearson’s correlation and intra-class correlation coeffi-
cients (ICC; the threshold goal of >0.60 [23]) were cal-
culated and a t-test used for the comparison of SOBDA
baseline score and SOBDA week before Day 28 score.
Convergent validity was assessed for the run-in popu-
lation by comparing SOBDA baseline score with BDI
and SGRQ total score at randomization (Day 1), and
baseline trough FEV1, using the Pearson’s correlation
coefficient. mMRC score at screening (Day −14 to
−7) was compared with SOBDA run-in Week 1 score
and CAT on Day 1 was compared with SOBDA base-
line score using Spearman rank order correlation
coefficient.
Known-groups validity was assessed for the run-in
population through comparing a) the mean SOBDA
baseline score in each BDI category (severity ranged
from 0, greatest impairment, to 12, least impairment)
as determined at Day 1 (randomization) and b) the
SOBDA run-in Week 1 scores in each mMRC category
as determined at screening. Both of these were evalu-
ated using analysis of covariance, adjusted for age, gen-
der, geographical region, and percent predicted FEV1 at
screening. This was repeated excluding percent pre-
dicted FEV1 due to the high level of data missing for
this variable.
Responsiveness
The responsiveness of the questionnaire was assessed by
comparing SOBDA score changes from baseline between
responders and non-responders defined by other assess-
ments (TDI, SGRQ, CAT, trough FEV1) within the ITT
population on Days 28, 84, and 168 (CAT was assessed
on Days 84 and 168, according to the study protocols of
DB2113360 and DB2113374). The minimum clinically
important TDI response was defined as a patient with a
TDI focal score of at least 1 unit [11–13]. The minimal
clinically important difference (MCID) in SGRQ was
defined as a patient with a decrease from baseline
(improvement) in SGRQ total score of 4 units or more
[11–13] and the MCID in CAT was defined as a patient
with a decrease from baseline (improvement) CAT score
of 2 units or more [24]. For trough FEV1, a patient with
a change from baseline of at least 100 mL was consid-
ered to be a responder [25].
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Thresholds for SOBDA response
Anchor-based methods and examination of the cumula-
tive proportions of responders and non-responders in
the ITT population were used to establish the threshold
for SOBDA response [26, 27]. The FDA recommend that
the empiric evidence necessary to establish any PRO re-
sponder definition is obtained from anchor-based
methods, and that the chosen anchors must be easier to
interpret than the PRO itself [10]. As such, the three an-
chors used were: TDI and SGRQ in all four studies at
Days 28, 84, and 168, and CAT in Studies DB2113360
and DB2113374 at Days 84 and 168. All three of these
measures are widely used to assess patient benefit in
COPD clinical trials. In addition to the definitions of
minimal responses given above, score changes were
assessed in relation to other levels of improvement in
the anchor measures (i.e., no change or worse, minor,
moderate, major; definitions in Additional file 3). For
SGRQ and CAT, a minor improvement was considered
to be between one and two-times the MCID (4 units or
2 units, respectively [11–13]), while a moderate im-
provement was more than twice the MCID. For TDI
(where improvements range from 0 to +9 [18]), categor-
ies were defined as: minor improvement = 1–3; moderate
improvement = 4–6; and major improvement = 7–9. Cu-
mulative distribution plots of change in SOBDA score
categorized by each level of improvement were also
assessed.
Although they are no longer recommended (by the
FDA) as the sole approach to define responders [10],
distribution-based methods were used in support of the
anchor-based methods, following the methods detailed
in Revicki et al. [26] (where 0.2- and 0.3-times the stand-
ard deviation [SD] of a PRO was considered to be a
measurement of the minimal important difference) and
Wyrwich et al. [28] (who used one standard error of the
mean [SEM] to assess this) to provide supporting evi-




Overall, 4967 patients were included in the run-in popu-
lation and of these, 4713 patients were included in the
ITT population for this post hoc meta-analysis. Baseline
characteristics and treatment effects for the ITT popula-
tion were as reported in the primary publications of
Studies DB2113360 and DB2113374 by Decramer et al.
[12], DB2113361 by Celli et al. [11] and DB2113373 by
Donohue et al. [13] (Additional file 1). The mean age of
patients in these studies ranged from 62.9 to 64.6 years
across all studies and more than 85 % of the patients in
each study were Global initiative for Chronic Obstruct-
ive Lung Disease (GOLD) Stage II (moderate COPD) or
III (severe COPD), less than 15 % were GOLD Stage IV
(very severe COPD) and no patients were GOLD Stage I
(mild COPD) (Additional file 1).
Consistency, reliability, and validity
Internal consistency of the SOBDA questionnaire was
assessed using Cronbach’s alpha. Within this meta-
analysis, Cronbach’s alpha was 0.936 (n = 1500: the num-
ber of patients with a score for each of the 13 items on
the first day of the run-in period, i.e., completed the
SOBDA questionnaire daily with no answers of ‘I did
not do’).
Test-retest reliability was assessed in the subset of
patients who had a SOBDA score at baseline and during
the week prior to Day 28, and had a TDI focal score of 0
(a surrogate to indicate no change in dyspnea) at Day 28.
SOBDA scores had high test-retest reliability, as indicated
by the Pearson’s correlation coefficient of 0.86 and the
ICC of 0.85 between SOBDA scores at these two time
points. When the test-retest reliability was assessed using
a t-test to compare the mean difference between the
SOBDA baseline score and that of the week before Day 28
for these patients, the estimated difference was −0.08
(95 % confidence intervals [CI]: −0.10 to −0.06); n = 1443).
The effect size (difference between the SOBDA baseline
score and that of the week before Day 28 divided by the
SD of the baseline score) was −0.117.
In the assessment of convergent/divergent validity,
SOBDA baseline scores were compared with different
assessments for the run-in population. The correlations
between SOBDA baseline score and the two HRQoL
outcomes (SGRQ total score on Day 1 [Pearson’s cor-
relation coefficient = 0.59; n = 4398]; CAT on Day 1
[Spearman rank order correlation coefficient = 0.50; n =
1580]) were similar. When the SOBDA baseline score
was compared with BDI at Day 1, the correlation was
lower than the HRQoL outcomes, (BDI: Pearson’s cor-
relation coefficient = −0.42; n = 4495; contrary to
SOBDA, higher scores in BDI indicate less dyspnea,
hence the negative correlation). Two other correlations,
baseline trough FEV1 with SOBDA baseline scores
(Pearson’s correlation coefficient = −0.17; n = 4520) and
the clinician-reported mMRC scores at screening with
the SOBDA run-in Week 1 scores (Spearman rank
order correlation coefficient = 0.32; n = 4497) had lower
correlations.
To further examine the validity of the SOBDA ques-
tionnaire in assessing shortness of breath in patients
with COPD, known-groups validity was assessed in the
ITT population. The known-groups for this analysis
were mMRC scores at screening and BDI scores at Day 1.
An association was found between SOBDA run-in Week
1 score and the mMRC scores at screening (F-statistic =
138.52, p < 0.001; using an analysis of covariance including
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all covariates, age, gender and geographical region, %
predicted FEV1). Similarly an association was found be-
tween SOBDA baseline score and BDI score at Day 1
(F-statistic = 45.84, p < 0.001; with all covariates). There
was a high level of missing data for % predicted FEV1 at
baseline and when it was excluded as a covariate from
this analysis, the known-groups validity F-statistic was
279.49 (p < 0.001) for mMRC scores and 83.90 (p < 0.001)
for the BDI scores (Table 1). Pairwise comparisons of
SOBDA scores within each mMRC category showed that
the least squares (LS) mean SOBDA score increased as
the mMRC increased with all CIs for those comparisons
excluding zero. Again, the CIs for the pairwise compari-
sons of SOBDA scores within each BDI category also ex-
cluded zero.
Responsiveness
To determine if the SOBDA scores were responsive to
changes in COPD status as measured by other COPD-
related assessments (TDI, SGRQ, CAT, and trough
FEV1), patients in the ITT population were defined as
responders or non-responders according to these other
assessments and the SOBDA change scores for these
groups were examined. With each of the investigated as-
sessments and time points (TDI, SGRQ, and trough
FEV1: Day 28, 84, and 168; CAT: Days 84 and 168), LS
mean SOBDA change scores were statistically significantly
larger in responders compared with non-responders,
demonstrating the ability to measure less dyspnea with
daily activities (p < 0.001 for all assessments and all
time points; Fig. 1).
Thresholds of response using SOBDA scores
The threshold for SOBDA response was assessed using
three separate methods in the ITT population. The pri-
mary analysis employed anchor-based methods using
accepted definitions of MCID for each anchor. Patients
who were considered to have improved using TDI,
SGRQ, or CAT had decreases in their mean SOBDA
score at Day 168 (Table 2) and also at Days 28 and 84
(Additional file 4). These decreases in SOBDA score in-
creased with the level of improvement on the anchor
measure. Using these three assessments at Day 168 as
anchors, the following thresholds were calculated:
– Change scores associated with minor improvement:
−0.16 to −0.22
– Change scores associated with moderate
improvement: −0.30 and −0.37
– Change scores associated with major improvement:
−0.38 and −0.49
Secondly, based on cumulative distribution plots
(Fig. 2), the values representing minor improvement for
all three anchors fell in a change score range of −0.1
to −0.2 across most time points and supported the cal-
culated values for other levels of improvement.
Finally, with the distribution-based method, response
thresholds in SOBDA score were calculated to be −0.135
and −0.203 (0.2 and 0.3 times the SD of the baseline
scores, respectively; [26]). According to the SEM method
used by Wyrwich et al. [28], the threshold was −0.010.
As these scores were based on the SD and SEM, the
numbers were calculated as positive numbers. However,
within SOBDA scoring, a decrease in the score equates
with an improvement in dyspnea, therefore all thresh-
olds of SOBDA scores are negative and these were con-
verted to negative numbers for consistency.
Discussion
The results of this confirmatory meta-analysis extend
the results of previous SOBDA validation studies [7, 8]
and demonstrate the consistency, reliability, validity, and
responsiveness of the SOBDA questionnaire within a
large RCT patient population (N = 4967). In addition,
the definition of a minimum response threshold for
SOBDA score was identified as a decrease from baseline
of 0.2 using three separate methods, refining the value
within the minimal important difference range of −0.1
to −0.2 previously reported in the smaller SOBDA de-
velopment study with 547 patients [8].
Within the large patient group used for this meta-
analysis, the SOBDA questionnaire was found to demon-
strate consistency and test-retest reliability in measuring
patient dyspnea with daily activities. The Pearson’s
correlation coefficient and the ICC between SOBDA
scores in patients with no change in dyspnea, and also
Cronbach’s alpha for this meta-analysis, were similar
to the two previously published studies using SOBDA
[7, 8]. The test-retest reliability was assessed using scores
from patients whose clinician endorsed zero for the TDI
focal score. Although there was a statistically significant
difference in this assessment (p < 0.001), which may have
been suggestive of a score change, it was likely due to the
large patient population studied. The two earlier studies
assessed the SOBDA questionnaire in moderate popula-
tion sizes and found no statistically significant difference
between SOBDA scores in the direct measure of patient
global assessment of change (PGAC) [7, 8].
The convergent validity correlation between the
SOBDA score and SGRQ total score was strong and
consistent with a prior SOBDA development study [7].
This was also reflected in the correlation between
SOBDA and CAT scores since the SGRQ and CAT
measure closely related concepts [20]. While the two
previous studies also measured the convergent validity
correlation coefficient between the SOBDA score and
other dyspnea assessments (PGAC, Clinician Global
Tabberer et al. Health and Quality of Life Outcomes  (2015) 13:177 Page 5 of 10
Table 1 Known-groups validity: the LS mean SOBDA weekly score by mMRC and by BDI response categories
ANCOVA excluding percent predicted FEV1 at screening
mMRC scorea at screening
(Day -14 to -7)
mMRC, LS mean run-in
Week 1 SOBDA score (SE); n
BDI score at randomization
(Day 1)
BDI, LS mean baseline
SOBDA score (SE); n
BDI score at randomization
(Day 1)
BDI, LS mean baseline
SOBDA score (SE); n
0–1 0 0 2.73 (0.108); 32 7 1.84 (0.021); 817
2 1.83 (0.012); 2939 1 2.63 (0.109); 31 8 1.65 (0.029); 434
3 2.25 (0.017); 1395 2 2.57 (0.056); 117 9 1.59 (0.035); 307
4 2.62 (0.050); 163 3 2.48 (0.031); 391 10 1.40 (0.060); 103
4 2.30 (0.029); 427 11 1.38 (0.115); 28
5 2.14 (0.027); 499 12 1.49 (0.106); 33
6 2.00 (0.017); 1276
Overall F-statistic (p-value)* 279.49 (<0.001) Overall F-statistic (p-value)* 83.90 (<0.001)
ANCOVA analysis of covariance, BDI Baseline Dyspnea Index, FEV1 forced expiratory volume in 1 s, LS least squares, mMRC modified Medical Research Council Dyspnea Scale, SE standard error, SOBDA Shortness of
Breath with Daily Activities
aScore 0 = not troubled with breathlessness except during strenuous exercise to 4 = too breathless to leave the house or breathless when dressing or undressing


















Impression of Dyspnea-change, Chronic Respiratory
Disease Questionnaire- self-administered standardized
version) [7, 8], these analyses further determined the
convergent validity between SOBDA scores and BDI
scores, where there was also a strong correlation. How-
ever, the correlation of SOBDA scores with trough FEV1
was low, as anticipated due to the weak correlations
previously identified between dyspnea and trough FEV1
[29, 30]. Also, there was a weak correlation between
SOBDA score and mMRC, previously found by Watkins
et al. who suggested that this was due to the narrow
range of responses given by clinicians when measur-
ing mMRC [8]. The SOBDA questionnaire, therefore,
appears to correlate better with other patient completed
measures that provide stratification in levels of response,
rather than measures administered by an interviewer or
clinician. Within the current meta-analysis, SOBDA scores
were shown to have known-groups validity based on the
clinician-rated mMRC and interviewer-administered BDI.
The two prior studies demonstrated that this was also
the case for patient-completed mMRC and the clinician-
completed global impression of symptoms [7, 8].
This post hoc analysis was also conducted to confirm
a response threshold using an anchor-based and sup-
portive distribution-based approach. Previous studies
suggested a threshold for response in the range of −0.1
to −0.2 (where SOBDA weekly scores ranged from 1 to 4).
Both the anchor-based and distribution-based methods in
this study support a −0.2 threshold of minimum response.
Thresholds for moderate and major improvement were
not formally assessed, but the data suggest that a threshold
for moderate improvement would be a SOBDA score
change of −0.30 to −0.37 and for major improvement
would be a SOBDA score change of −0.38 to −0.49. These
results are in agreement with the review by Revicki et al.,













































Day 28 Day 84 Day 168
Responders (n) 2094 2086 1958
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Day 28 Day 84 Day 168
Responders (n) 2217 2001 1794








Fig. 1 Change in the SOBDA prior week score by TDI (a), SGRQ (b), CAT (c), and trough FEV1 (d) response. *Response was defined as a TDI focal score
of at least 1 unit. †Response was defined as a change from baseline in SGRQ total score of≤−4. ‡Response was defined as a change from baseline
in CAT score of≤−2 (studies DB2113360 and DB211374 only). §Response was defined as a change from baseline in trough FEV1 of ≥100 mL. Analyses
performed using analysis of covariance adjusted for SOBDA baseline score and geographic region. Error bars represent the 95 % CIs. CAT, COPD
Assessment Test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; LS, least squares; SGRQ, St
George’s Respiratory Questionnaire score; SOBDA, Shortness of Breath with Daily Activities; TDI, Transition Dyspnea Index
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Table 2 Thresholds calculated using change from baseline to SOBDA prior week score





















n 1375 1108 635 215 1331 437 1345 510 159 503
Mean change from baseline to
SOBDA prior week score (SD)
−0.09 (0.515) −0.22 (0.530) −0.30 (0.549) −0.49 (0.574) −0.02 (0.493) −0.17 (0.500) −0.37 (0.547) −0.10 (0.506) −0.16 (0.515) −0.38 (0.608)
CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, SD standard deviation, SGRQ St George’s Respiratory Questionnaire, SOBDA Shortness of Breath with Daily Activities, TDI Transitional
Dyspnea Index
aNo change or worse is defined as a score of 0 or less, minor improvement is defined as a score of 1–3, moderate improvement is defined as a score of 4–6 and major improvement is defined as a score of 7–9
bNo change or worse is defined as a change from baseline of > −4 units, minor improvement is defined as a change from baseline of > −8 to ≤ −4 units and moderate improvement is defined as a change from
baseline of ≤ −8 units
cNo change or worse is defined as a change from baseline of > −2 units, minor improvement is defined as a change from baseline of > −4 to ≤ −2 units, major improvement is defined as a change from baseline


















are recommended, but the distribution methods may pro-
vide guidance [26]. Revicki et al. considered the differences
between using 0.5, 0.3 and 0.2 times the SD as the minimal
difference and concluded that the 0.5 times the SD was
likely too large to be the minimal non-ignorable difference.
When considering missing data we found that comple-
tion of the SOBDA daily e-diary, measured by data
transmission, exceeded 90 % indicating that patients
were able to use the e-diary over an extended study
period. There were no important gender or country dif-
ferences in the incidence of ‘I did not do this activity
today’ responses for individual SOBDA questionnaire
items, indicating that the final item pool is appropriate
for both genders and across multiple countries (GSK,
data on file).
This meta-analysis of SOBDA data had its limitations.
Due to the inclusion criteria used, the majority of pa-
tients in this meta-analysis were at GOLD Stage II or III
at baseline (Additional file 1), with approximately 10 %
(n = 494) at GOLD Stage IV. Future investigations into
the SOBDA questionnaire could involve a more detailed
analysis of this GOLD Stage IV subgroup and also stud-
ies to include those at the very early stages of this dis-
ease. The results presented here are applicable to a RCT
population with moderate–very severe COPD. It remains
unclear how the SOBDA questionnaire would perform
in the overall COPD population or in an exacerbating
COPD population, particularly as patients were with-
drawn from these studies if they had an exacerbation.
The SOBDA questionnaire was developed as a daily
e-diary for use in clinical research, rather than for use in
clinical practice where the patient burden of completing
a daily diary is likely to be too onerous. Through its use
within clinical trials, the SOBDA questionnaire may be
able to contribute to the assessment of new therapies
that improve dyspnea in patients with COPD.
Conclusions
The findings of this meta-analysis confirm and extend
the results of previous SOBDA validation studies, and
demonstrate the consistency, reliability, and validity of
the SOBDA questionnaire under RCT conditions. A
minimum threshold of response in SOBDA score was
confirmed as a change of −0.20. With support for the
SOBDA questionnaire proven to be consistent, valid,
and reliable in patients with moderate–very severe
COPD, this response threshold could be incorporated
into the assessments used in future RCTs of COPD
therapies.
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Additional file 1: Design of the four studies and patient baseline
characteristics. (DOC 64 kb)
Additional file 2: Schematic of the study design used in each of the
four included studies. *Studies DB2113361 [11] and DB2113373 [13].
†Studies DB2113360 (Study 1) and DB2113374 (Study 2) [12]. Baseline
SOBDA score refers to data collected during the 7 days prior to V2.
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Additional file 3: Definitions of the levels of improvement used for
analysis. (DOC 29 kb)
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Fig. 2 One of the cumulative distribution plots used to calculate SOBDA thresholds. TDI response category definitions: major improvement = score of
7–9, moderate improvement = score of 4–6, minor improvement = score of 1–3, no change or worse = score of 0 or less. SOBDA, Shortness of Breath
with Daily Activities; TDI, Transitional Dyspnea Index
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